Plants are quietly borrowing tricks from bacteria, repurposing foreign genes to build complex molecules that look a lot like ...

Traws Pharma, Inc. (TRAW) has disclosed a new risk, in the Corporate Activity and Growth category. The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc.’s future ...

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive ...

By the end of 2026, the outlines of the next-generation pharmaceutical company will already be taking shape. Organizations that reimagine discovery, reinvent operations, and redesign patient ...

Fierce’s Rebecca Willumson sat down with Swoop President Scott Rines – live at Digital Pharma East – to discuss some of the most pressing issues in pharma marketing today. Rines kicks off by debunking ...

Lumos Pharma (NASDAQ:LUMO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. Now, after several years spent ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

My initial rating of Abbott Laboratories is a buy, agreeing with today's Wall Street consensus. The future growth indicators, diversified portfolio across many clinical segments, and leading roles in ...

Pharma marketers frequently cite the need to craft marketing that’s rooted in empathy. For Katie Williams, chief marketing officer (CMO) at GSK’s consumer health spinoff Haleon, empathy manifests as ...